Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus PENTETATE CALCIUM TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus PENTETATE CALCIUM TRISODIUM.
CUPRIMINE vs PENTETATE CALCIUM TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
None Documented
None Documented
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours.
Category C
Category C
Chelating Agent
Chelating Agent